IOL Myopia, Hyperopia Studies Should Include 3-Year Follow Up - FDA Panel
This article was originally published in The Gray Sheet
Executive SummaryIntraocular lens manufacturers pursuing approval for myopia and hyperopia indications should conduct 550-patient studies with three-year follow up, FDA's Ophthalmic Devices Advisory Panel concluded at an Oct. 23 meeting in Silver Spring, Maryland.
You may also be interested in...
Biogen’s “recipe-driven qualification” knowledge management program standardizes data collection and reporting in the laboratory, with efficiency gains of 66%.